-

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

CHICAGO--(BUSINESS WIRE)--Anna Chukaeva has been appointed as Senior Vice President, Head of Corporate Development and Bioinformatics of Exicure, Inc. (“the Company”) (Nasdaq: XCUR). Anna will spearhead investments, acquisitions, and strategic partnerships. She will also push into leveraging data and AI for drug discovery and diagnostics.

Anna was the co-founder, President and COO of Carta Healthcare, an AI healthcare data company which has raised over $50 million in venture financing. While leading operations for 5 years, she directly led the 40-person, multi-national engineering and product team to design and develop enterprise-scale data software products adopted by hospital systems nationwide.

She received a bachelor’s degree in mathematics, a master’s in economics, and an MBA from Stanford.

About Exicure, Inc.

Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.

Contacts

Josh Miller
847-673-1700
media@exicuretx.com

Exicure, Inc.

NASDAQ:XCUR

Release Summary
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
Release Versions

Contacts

Josh Miller
847-673-1700
media@exicuretx.com

More News From Exicure, Inc.

Exicure, Inc. Reports First Quarter 2025 Financial Results

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Q1 2025 earnings release...

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q...

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant...
Back to Newsroom